BioAtla BCAB
NASDAQ BCAB
$1.40 +0.08 (+6.06%)
At close: Sep 8, 2026 · 4:00 PM EDT

BioAtla (BCAB) Retained Earnings (2020 - 2026)

BioAtla's (BCAB) quarterly Retained Earnings came in at -$551.5 million in Q2 2026, down 6.04% on a YoY basis from -$587.0 million in Q2 2025, and little changed quarter-over-quarter from -$552.0 million in Q1 2026.

Analysis

BioAtla (BCAB) Retained Earnings (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Retained Earnings for 7 consecutive years, with -$551.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Retained Earnings fell 6.04% year-over-year to -$551.5 million; the trailing twelve-month figure through Jun 2026 stood at -$551.5 million (down 6.04% YoY), and the FY2025 full-year result was -$545.6 million, down 209.06% from the prior year.
  • Retained Earnings steadied at -$551.5 million in Q2 2026 per BCAB's latest filing, from -$552.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $501.9 million in Q1 2025 and bottomed at -$552.0 million in Q1 2026.
  • Historically, Retained Earnings has averaged $188.1 million across 5 years, with a median of $474.9 million in 2022.
  • The sharpest annual moves came in 2022 and 2026: Retained Earnings surged 31.12% in 2022, then tumbled 209.98% in 2026.
  • Over 5 years, Retained Earnings stood at $473.1 million in 2022, then rose by 2.92% to $486.9 million in 2023, then grew by 2.75% to $500.3 million in 2024, then slumped by 209.06% to -$545.6 million in 2025, then fell by 1.08% to -$551.5 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods registered -$551.5 million, -$552.0 million, and -$545.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Amgen 206.69 Bn 192.70 Bn 7.24 Bn -22.28 Bn
2 Gilead Sciences 179.87 Bn 176.70 Bn 6.22 Bn 9.53 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 15.69 Bn
4 Regeneron Pharmaceuticals 81.70 Bn 73.71 Bn 3.93 Bn 37.62 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 558.00 Mn
6 Moderna 54.28 Bn 49.14 Bn 52.00 Mn 5.10 Bn
7 Alnylam Pharmaceuticals 33.02 Bn 29.71 Bn 992.69 Mn -6.33 Bn
8 Biogen 31.93 Bn 30.64 Bn 1.96 Bn 20.97 Bn
9 Roivant Sciences 29.27 Bn 29.27 Bn 1.16 Mn 5.13 Bn
10 BioAtla 2.33 Mn 2.33 Mn - -551.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -551.54 Mn
Mar 31, 2026 -552.00 Mn
Dec 31, 2025 -545.65 Mn
Sep 30, 2025 -535.90 Mn
Jun 30, 2025 -520.10 Mn
Mar 31, 2025 501.91 Mn
Dec 31, 2024 500.30 Mn
Sep 30, 2024 494.12 Mn
Jun 30, 2024 491.93 Mn
Mar 31, 2024 489.21 Mn
Dec 31, 2023 486.93 Mn
Sep 30, 2023 484.04 Mn
Jun 30, 2023 480.52 Mn
Mar 31, 2023 476.68 Mn
Dec 31, 2022 473.14 Mn
Sep 30, 2022 407.89 Mn
Jun 30, 2022 404.43 Mn
Mar 31, 2022 400.62 Mn
Dec 31, 2021 397.14 Mn
Sep 30, 2021 393.58 Mn